会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 21. 发明申请
    • METHOD FOR PREDICTING IMMUNE RESPONSE TO NEOPLASTIC DISEASE BASED ON mRNA EXPRESSION PROFILE IN NEOPLASTIC CELLS AND STIMULATED LEUKOCYTES
    • 基于神经细胞和刺激白血病细胞中mRNA表达谱的免疫应答预防神经病变的方法
    • US20090111128A1
    • 2009-04-30
    • US11917151
    • 2006-06-08
    • Masato Mitsuhashi
    • Masato Mitsuhashi
    • G01N33/53
    • G01N33/505C12Q1/6806C12Q1/6886C12Q2600/118C12Q2600/158G01N33/574
    • Tumor necrosis factor (TNF) is capable of inducing apoptosis by interacting with specific TNF receptors on the surface of cancer cells. Because multiple members of TNF ligand and receptor are present within each superfamily, over 300 different ligand-receptor combinations exist. Activated blood leukocytes produce TNF as part of the immune response to cancer, as well as producing chemokines to attract other leukocytes to the site. A method is disclosed of detecting significant induction of a variety of TNF superfamily subtype and chemokine mRNAs in blood leukocytes when whole blood is exposed to heat-aggregated IgG or anti-T cell receptor antibodies as a model of immune system interactions. Substantial individual-to-individual variation is observed in TNF subtypes and chemokines induced. Since peripheral blood leukocytes are the supply of anti-cancer immune cells, the quantitation of ex vivo inducibility of appropriate TNF ligands and chemokines in blood will be useful in individualized cancer immunotherapy. If the tumor mass is small, such as with early invisible metastatic lesions, appropriate TNF assaults may be sufficient to prevent relapse.
    • 肿瘤坏死因子(TNF)能够通过与癌细胞表面的特异性TNF受体相互作用诱导细胞凋亡。 由于TNF配体和受体的多个成员存在于每个超家族中,所以存在超过300种不同的配体 - 受体组合。 活化的血液白细胞产生TNF作为对癌症的免疫应答的一部分,以及产生趋化因子以吸引其他白细胞到该部位。 公开了当全血暴露于作为免疫系统相互作用的模型的热聚集的IgG或抗T细胞受体抗体时,检测血白细胞中各种TNF超家族亚型和趋化因子mRNA的显着诱导的方法。 在TNF亚型和趋化因子诱导中观察到显着的个体与个体差异。 由于外周血白细胞是抗癌免疫细胞的供应,所以在个体化的癌症免疫治疗中定量适当的TNF配体和趋化因子在血液中的离体诱导性将是有用的。 如果肿瘤质量小,如早期隐形转移性病变,适当的TNF攻击可能足以防止复发。
    • 22. 发明申请
    • Method of Measuring Cancer Susceptibility
    • 测量癌症易感性的方法
    • US20080261207A1
    • 2008-10-23
    • US11597505
    • 2005-05-25
    • Masato Mitsuhashi
    • Masato Mitsuhashi
    • C12Q1/68C12Q1/02
    • C12Q1/6886C12Q2600/106C12Q2600/136C12Q2600/158G01N33/5017G01N2800/40G01N2800/50
    • An individual's susceptibility to cancer is assessed based on the individual's cellular response to mutagenic agents such as radiation. The level of a growth-suppressing marker is measured before and after the individual's cells are exposed to the mutagenic agent. The individual's susceptibility to cancer as a result of the mutagenic agent is correlated with the degree to which the growth-suppressing marker is induced by exposure to the agent. A method is also disclosed for assessing cancer prophylaxis effects of compounds, such as vitamins or food extracts, in individuals. Cells from an individual are incubated with at least one compound in vitro, or the compound is directly administered to the individual, after which some of the incubated cells, as well as non-incubated cells, are exposed to a mutagenic agent such as ionizing radiation. The level of the growth-suppressing marker in the cells incubated with the compound and exposed to the mutagenic agent is then compared with the level in the non-incubated cells exposed to the agent. The cancer prophylaxis effects of the compound are correlated with a higher level of the marker in the incubated cells.
    • 个体对癌症的敏感性是根据个体对诱变剂如辐射的细胞反应进行评估的。 在个体细胞暴露于诱变剂之前和之后测量生长抑制标记的水平。 致敏物质对个体的癌症易感性与通过暴露于药剂诱导生长抑制标记的程度相关。 还公开了一种用于评估化合物(例如维生素或食物提取物)在个体中的癌症预防效果的方法。 来自个体的细胞在体外与至少一种化合物一起温育,或者将化合物直接施用于个体,之后将一些培养的细胞以及未孵育的细胞暴露于诱变剂如电离辐射 。 然后将与化合物孵育并暴露于诱变剂的细胞中的生长抑制标记物的水平与暴露于该试剂的未孵育细胞中的水平进行比较。 该化合物的癌症预防作用与培养细胞中较高水平的标记物相关。